Predict your next investment

Venture Capital
bioventuresinvestors.com

See what CB Insights has to offer

Investments

67

Portfolio Exits

11

Funds

5

About BioVentures Investors

BioVentures Investors has three funds currently under management; all focused on the commercial development of advanced technology in Life Sciences and Healthcare.BioVentures currently has over $145 million under management. Investments in individual companies typically range from $3 to $7 million dollars. Fund Partners typically take board seats, or in those transactions in which we do not lead or co-lead, attend all Board meetings as observers.

BioVentures Investors Headquarter Location

70 Walnut Street Suite 302

Wellesley Hills, Massachusetts, 02481,

United States

781-489-2105

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BioVentures Investors News

BRAINBox Closes $23M Series A Round

Dec 10, 2020

BRAINBox Solutions has announced the initial closing on a $23 million Series A financing to support the clinical development of the company's BRAINBox TBI (Traumatic Brain Injury) Test to aid both in the diagnosis and prognosis of mild TBI (concussion). BioVentures Investors led the financing round and was joined by the Tauber Foundation, the Virginia Tech Carilion Innovation and Seed Funds, Genoa VC, Pharmakon Holdings LLC, Astia Angels and additional qualified investors, including Kevin Love, professional basketball player and mental health advocate. BRAINBox Solutions is developing the first AI-enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion. The company seeks to establish a clinical best-practice standard for the diagnosis and prognosis of concussion. The product incorporates a panel of proprietary, patented blood biomarkers that can be read in a few moments on a point-of-care instrument or using standard laboratory systems, as well as neurocognitive testing, to provide a single-system score that measures the severity of the injury and guide treatment. The company is led by key physician and scientific thought leaders in the field and an experienced, clinically focused management team. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

BioVentures Investors Investments

67 Investments

BioVentures Investors has made 67 investments. Their latest investment was in PathologyWatch as part of their Series A - II on December 12, 2020.

CBI Logo

BioVentures Investors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/17/2020

Series A - II

PathologyWatch

$2M

Yes

2

12/2/2020

Series A

BRAINBox

$23M

Yes

3

11/12/2019

Series B

Sonomotion

$10M

No

7

10/1/2019

Series D - II

Subscribe to see more

$99M

Subscribe to see more

10

4/18/2019

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/17/2020

12/2/2020

11/12/2019

10/1/2019

4/18/2019

Round

Series A - II

Series A

Series B

Series D - II

Series A - II

Company

PathologyWatch

BRAINBox

Sonomotion

Subscribe to see more

Subscribe to see more

Amount

$2M

$23M

$10M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

7

10

10

BioVentures Investors Portfolio Exits

11 Portfolio Exits

BioVentures Investors has 11 portfolio exits. Their latest portfolio exit was Hydra Biosciences on December 14, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/14/2018

Asset Sale

2

3/21/2013

IPO

$991

2

12/20/2012

Acquired

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

12/14/2018

3/21/2013

12/20/2012

00/00/0000

00/00/0000

Exit

Asset Sale

IPO

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

BioVentures Investors Fund History

5 Fund Histories

BioVentures Investors has 5 funds, including Bioventures Investors Medtech Growth Capital.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/15/2020

Bioventures Investors Medtech Growth Capital

$204.5M

2

10/7/2016

BioVentures Investors IV

Subscribe to see more

$99M

10

1/1/2007

BioVentures Investors III LP

Subscribe to see more

$99M

10

5/31/2003

BioVentures Investors II LP

Subscribe to see more

$99M

10

12/31/1999

BioVentures Investors LP

Subscribe to see more

$99M

10

Closing Date

12/15/2020

10/7/2016

1/1/2007

5/31/2003

12/31/1999

Fund

Bioventures Investors Medtech Growth Capital

BioVentures Investors IV

BioVentures Investors III LP

BioVentures Investors II LP

BioVentures Investors LP

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$204.5M

$99M

$99M

$99M

$99M

Sources

2

10

10

10

10

BioVentures Investors Team

5 Team Members

BioVentures Investors has 5 team members, including current General Partner, Peter Feinstein.

Name

Work History

Title

Status

Marc E. Goldberg

Founder

Current

Peter Feinstein

General Partner

Current

Jonathan P. Gertler

SVB Leerink, Adams Harkness, Massachusetts General Hospital, and Yale School of Medicine

Managing Director

Current

Jeffrey T. Barnes

General Partner

Current

Walter A. Gilbert

General Partner

Current

Name

Marc E. Goldberg

Peter Feinstein

Jonathan P. Gertler

Jeffrey T. Barnes

Walter A. Gilbert

Work History

SVB Leerink, Adams Harkness, Massachusetts General Hospital, and Yale School of Medicine

Title

Founder

General Partner

Managing Director

General Partner

General Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.